OncoMatch/Clinical Trials/NCT06365853
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Is NCT06365853 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mirvetuximab Soravtansine and Lubricating Eye Drops for recurrent ovarian cancer.
Treatment: Mirvetuximab Soravtansine · Lubricating Eye Drops · Prednisolone acetate ophthalmic suspension 1% eye drops · Brimonidine tartrate ophthalmic solution eye drops — The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: FOLR1 high expression (≥ 75% cells with ≥ 2+ membrane staining intensity by VENTANA FOLR1 Assay) (≥ 75% cells with ≥ 2+ membrane staining intensity)
FRα positive (FRα high) as defined by either the VENTANA FOLR1 (FOLR-2.1) IUO Assay, or the VENTANA FOLR1 ( FOLR1-2.1) RxDx Assay (≥ 75% cells exhibit ≥ 2+ membrane staining intensity)
Allowed: BRCA1 mutation (tumor or germline)
Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi)
Allowed: BRCA2 mutation (tumor or germline)
Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi)
Prior therapy
Must have received: poly (ADP-ribose) polymerase inhibitor
Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi)
Cannot have received: FRα-targeting agent (mirvetuximab soravtansine)
Participants who received prior treatment with MIRV or other FRα-targeting agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Los Angeles /ID# 269339 · Los Angeles, California
- Norton Cancer Institute - St. Matthews /ID# 269070 · Louisville, Kentucky
- Holy Cross Hospital - Silver Spring /ID# 269344 · Silver Spring, Maryland
- Mercy David C. Pratt Cancer Center /ID# 269350 · St Louis, Missouri
- The Center Of Hope /ID# 269348 · Reno, Nevada
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify